Immunovant Shares Surge on Promising Arthritis Drug Data
Immunovant shares soared 35% after its experimental rheumatoid arthritis drug, IMVT-1402, demonstrated high response rates in a difficult-to-treat patient population, prompting a re-rating by Wall Street.
Markets
